齐拉西酮与氟哌啶醇注射液治疗精神分裂症急性激越症状的临床对照研究  

Clinical comparative study of intramuscular ziprasidone versus haloperidol in the treatment of acute agitation symptoms of schizophrenia

作　　者：张晓阳[1] 杨晓江[1] 王哲伟[1] 

机构地区：[1]福建省泉州市第三医院,362000

出　　处：《四川精神卫生》2015年第1期42-44,共3页Sichuan Mental Health

摘　　要：目的评价齐拉西酮与氟哌啶醇注射液治疗精神分裂症急性激越症状的临床疗效和安全性.方法采用最小不平衡指数法将94例具有急性激越症状的精神分裂症患者分为齐拉西酮组和氟哌啶醇组各47例.齐拉西酮组给予齐拉西酮注射液,起始剂量为10～20mg,根据病情需要4～6h后可重复使用,最大剂量不超过40mg/d;氟哌定醇组给予氟哌定醇注射液,起始剂量为5～10mg,4～6h后可重复使用,最大剂量不超过30mg/d.均臀大肌深部注射,疗程3天.采用阳性与阴性症状量表兴奋因子（PANSS-EC）评定疗效,采用副反应量表（TESS）评定副反应.结果齐拉西酮组与氟哌啶醇组PANSS-EC减分率差异无统计学意义[（45.29±13.84）%vs.（47.56±14.49）%,t=0.068,P〉0.05].齐拉西酮组与氟哌啶醇组临床总有效率差异无统计学意义（53.19%vs.48.94%,χ^2=0.072,P〉0.05）.齐拉西酮组与氟哌啶醇组不良反应发生率差异有统计学意义（29.8%vs.49.8%,χ^2=9.035,P〈0.05）.结论齐拉西酮注射液治疗精神分裂症急性激越症状的效果与氟哌啶醇相当,安全性优于氟哌啶醇.Objective To estimate the clinical efficacy and safety of intramuscular mesylate ziprasidone in the treatment of acute agitation in schizophrenia. Methods 94 cases of schizophrenia patients with symptoms of acute agitation were divided into ziprasidone group and haloperidol group by minimum imbalance index method. The ziprasidone group were treated with intramuscular ziprasidone 10~ 40 mg,and the haloperidol group were treated with intramuscular haloperidol 5 ~ 30 mg by deep glutes injection. The treatment course was 3 days. The efficacy was assessed with PANSS-EC and the side effects were assessed with TESS. Results The difference of the decreasing rates on PANSS-EC of the two groups was not significant [( 45. 29 ± 13. 84) % vs.( 47. 56 ± 14. 49) %,t = 0. 068,P >0. 05]. The difference of the clinical total effective rate between the two groups was not significant( 53. 19% vs. 48. 94%,χ2= 0. 072,P> 0. 05). The side effects rate of the two groups was significant( 29. 8% vs. 49. 8%,χ2= 9. 035,P < 0. 05). Conclusion Intramuscular ziprasidone is as effective as haloperidol in the treatment of acute agitation in schizophrenia,and it's safer than haloperidol.

关 键 词：齐拉西酮 氟哌啶醇 精神分裂症 激越 

分 类 号：R749.3[医药卫生—神经病学与精神病学]